Navigation Links
EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
Date:2/3/2010

VIENNA, Austria, February 3 /PRNewswire/ -- EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has received a cash injection of EUR 2 million from existing shareholders.

The Company will use these funds to swiftly add new enzyme families to its product portfolio and to accelerate the development of international markets. At the same time, EUCODIS Bioscience is expanding its manufacturing capacity in pace with growing customer demand for its novel enzymes.

Commenting on the capital injection Thomas Fischer, CEO of EUCODIS Bioscience, said: "Following several product launches in 2009 and the recent expansion of our lipases family to 20 enzymes we continue to build our order book. Accordingly, our revenues will finance a good part of our expenses and investments this year."

Fischer continued: "Given the wealth of business opportunities in front of us, we are extremely pleased that the cash injection will help us to broaden our product range and to ramp up our sales and marketing efforts."

EUCODIS Bioscience' shareholders Pontis Capital, Wiener Wachstumsfonds, IBG, and ARAX participated in the cash injection.

Harald Schuerz, Managing Director of Wiener Wachstumsfonds, commented: "We are delighted that the market clearly confirms the business model of EUCODIS Bioscience. The commercial focus and the industrial mindset of their team are impressive. In light of their track record and the market potential, this company will soon be an Austrian IPO candidate."

Thomas Moser, Managing Partner at Pontis Capital, commented: "We have been impressed with the progress EUCODIS Bioscience has made in commercializing their experience in enzyme development. In addition, they have established a proven technology for the directed evolution of enzymes and have developed a unique expertise in manufacturing specialty enzymes. This provides the right ingredients to make EUCODIS Bioscience a preeminent supplier to the white biotechnology industry."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company develops and markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Thomas Fischer, MBA
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net

SOURCE EUCODIS Bioscience


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Appoints Thomas Fischer as New CEO
2. EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
3. EUCODIS Bioscience Launches Lipase Portfolio
4. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
5. EUCODIS Bioscience Signs Research Agreement With Genencor
6. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
7. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
8. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
9. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
10. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
11. YM BioSciences announces result of Cytopia shareholder vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... ... June 16, 2017 , ... Cambridge Semantics , the ... Anzo Smart Data Lake® (Anzo SDL) solution was named a finalist in ... & Information Industry Association (SIIA) CODiE Awards. , Finalists represent the best ...
(Date:6/15/2017)... Philadelphia, PA (PRWEB) , ... June 15, 2017 ... ... Center’s Esther Klein Gallery (EKG) follows an artist’s journey through creative experimentation and ... 22, 2017 and runs through July 22nd. An opening reception will be held ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... 8th to discuss the initiative steered by the executive search firm, “Building Value ... of the Board of Directors of Foundation Medicine, led an open discussion with ...
(Date:6/14/2017)... CA (PRWEB) , ... June 14, 2017 , ... ... cancer diagnostics and personalized medicine technology, today announced four new distribution agreements for ... over the cancer care cycle. The commercial agreements will make ClearID available immediately ...
Breaking Biology Technology:
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
Breaking Biology News(10 mins):